Literature DB >> 12110993

Differential modulation of efficiency in a food-rewarded "differential reinforcement of low-rate" 72-s schedule in rats by norepinephrine and serotonin reuptake inhibitors.

Anne Dekeyne1, Alain Gobert, Agnès Auclair, Sylvie Girardon, Mark J Millan.   

Abstract

RATIONALE: The differential reinforcement of low-rate 72-s (DRL 72-s) schedule, in which rats must withhold a response for at least 72 s to obtain a reward (generally water), is an attractive procedure for the characterisation of potential antidepressant agents. Indeed, several antidepressants have been shown to improve efficiency (ratio of reinforcement rate to response rate) in this model, either by decreasing response rates and/or by increasing reinforcement rates.
OBJECTIVE: Herein, we compared the actions of antidepressants known to inhibit serotonin (5-HT), norepinephrine (NE) and/or dopamine (DA) reuptake in a food-rewarded DRL 72-s schedule.
METHODS: Rats trained in a food-rewarded DRL 72-s schedule and showing stable baseline performance were administered with drugs i.p. once a week. In independent experiments, the influence of drugs on food intake, spontaneous locomotor activity and extracellular levels of monoamines in the frontal cortex was evaluated.
RESULTS: In confirmation of previous studies, the tricyclic agent imipramine (10.0 mg/kg) and the "atypical" agent mianserin (40.0 mg/kg) significantly increased efficiency. In analogy, the selective NE reuptake inhibitors (NARIs) desipramine (20.0 mg/kg), nortriptyline (2.5 mg/kg) and reboxetine (0.63 mg/kg) all displayed marked enhancements in efficiency. In contrast, the selective 5-HT reuptake inhibitors (SSRIs) citalopram (10.0 mg/kg), fluvoxamine (10.0 mg/kg) and paroxetine (10.0 mg/kg) all significantly decreased efficiency. The mixed 5-HT/NE reuptake inhibitors (SNRIs) venlafaxine (2.5 mg/kg, 10.0 mg/kg) and S33005 (0.16-10.0 mg/kg), likewise, did not increase efficiency. Further, the DA reuptake inhibitors (DARIs) bupropion (0.16-10.0 mg/kg) and GBR12935 (0.63-10.0 mg/kg) had no effect on DRL 72-s performance. All drug classes exerted a similar, mild inhibitory influence on food intake and locomotor behaviour. Imipramine, mianserin and NARIs markedly increased extracellular levels of NE, and SSRIs elevated levels of 5-HT, while SSRIs augmented levels of both.
CONCLUSIONS: The present experimental procedure demonstrates, in analogy to imipramine and mianserin, robust and consistent increases in efficiency with NARIs. Their effects may be distinguished from a decrease in efficiency elicited by SSRIs, and a lack of activity of SNRIs and DARIs. While the reasons underlying the ineffectiveness of SSRIs (in contrast to previous studies) remain to be clarified, these data underline the importance of adrenergic mechanisms in the control of behaviour under conditions of delayed responding. Further, they support the interest of DRL 72-s procedures for the characterisation of diverse classes of antidepressant agent.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12110993     DOI: 10.1007/s00213-002-1070-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  11 in total

1.  Diminished conditioned responding to the nicotine stimulus by antidepressant drugs with differing specificity for the serotonin and norepinephrine transporter.

Authors:  Amanda M Dion; Scott C Sanderson; L Charles Murrin; Rick A Bevins
Journal:  Pharmacol Biochem Behav       Date:  2011-10-08       Impact factor: 3.533

2.  α₂- and β-adrenoceptors involvement in nortriptyline modulation of auditory sustained attention and impulsivity.

Authors:  Swagata Roychowdhury; Zulma Peña-Contreras; Jason Tam; Amulya Yadlapalli; Lu Dinh; Justin Andrew Nichols; Debarshi Basu; Marco Atzori
Journal:  Psychopharmacology (Berl)       Date:  2012-01-21       Impact factor: 4.530

3.  d-Amphetamine and methylmercury exposure during adolescence alters sensitivity to monoamine uptake inhibitors in adult mice.

Authors:  Steven R Boomhower; M Christopher Newland
Journal:  Neurotoxicology       Date:  2019-02-12       Impact factor: 4.294

4.  Nicotine-induced impulsive action: sensitization and attenuation by mecamylamine.

Authors:  Ari P Kirshenbaum; Eric R Jackson; Seth J Brown; Jason R Fuchs; Betsie C Miltner; Adam H Doughty
Journal:  Behav Pharmacol       Date:  2011-06       Impact factor: 2.293

5.  The selective serotonin reuptake inhibitor paroxetine decreases breakpoint of rats engaging in a progressive ratio licking task for sucrose and quinine solutions.

Authors:  Clare M Mathes; Jillian R Gregson; Alan C Spector
Journal:  Chem Senses       Date:  2012-12-19       Impact factor: 3.160

6.  Postsynaptic alpha-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior.

Authors:  Han-Ting Zhang; Lisa R Whisler; Ying Huang; Yang Xiang; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

7.  Long-lasting behavioral effects and recognition memory deficit induced by chronic mild stress in mice: effect of antidepressant treatment.

Authors:  N Elizalde; F J Gil-Bea; M J Ramírez; B Aisa; B Lasheras; J Del Rio; R M Tordera
Journal:  Psychopharmacology (Berl)       Date:  2008-05-10       Impact factor: 4.530

8.  Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal.

Authors:  V C Wing; M Shoaib
Journal:  Psychopharmacology (Berl)       Date:  2007-08-10       Impact factor: 4.530

Review 9.  Is there an inhibitory-response-control system in the rat? Evidence from anatomical and pharmacological studies of behavioral inhibition.

Authors:  Dawn M Eagle; Christelle Baunez
Journal:  Neurosci Biobehav Rev       Date:  2009-07-15       Impact factor: 8.989

10.  Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.

Authors:  Ciara McCabe; Zevic Mishor; Philip J Cowen; Catherine J Harmer
Journal:  Biol Psychiatry       Date:  2009-12-24       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.